Seroprevalence of anti-hepatitis E virus (HEV) in a Korean population: comparison of two commercial anti-HEV assays

• Main Authors: Park Hyun, Jeong Sook-Hyang, Kim Jin-Wook, Woo Byung-Hyun, Lee Dong, Kim Hyun, Ahn Soyeon
• Format: Article
• Language: English
• Published: BMC 2012-06-01
• Series: BMC Infectious Diseases
• Subjects: Hepatitis E virus; Seroprevalence; Anti-HEV assay; Korea
• Online Access: http://www.biomedcentral.com/1471-2334/12/142

<p>Abstract</p> <p>Background</p> <p>Hepatitis E virus (HEV) has emerged as an important cause of epidemic and sporadic acute viral hepatitis worldwide. This study investigated the seroprevalence of anti-HEV in a Korean population and compared the performance of two commercially available anti-HEV assays.</p> <p>Methods</p> <p>A total 147 health-check examinees were randomly sampled as matched to the age- and sex- adjusted standard population based on the Korean National Census of 2007. Serum immunoglobulin G anti-HEV was determined by using the Genelabs assay (Genelabs, Singapore) and the Wantai assay (Wantai, Beijing, China).</p> <p>Results</p> <p>The overall anti-HEV seroprevalence was 23.1% (95% CI, 16.1-30.1%) using the Wantai assay and 14.3% (95% CI, 8.3-20.3%) using the Genelabs assay. Only 12 samples (8.1%) were positive for anti-HEV as measured by both assays; agreement between the two assays was poor (kappa value of 0.315). The anti-HEV seroprevalence increased with age from 2% and 3% in the people younger than 20-years-of-age to 34.6% and 42.3% in those over 59-years-of-age by the Genelabs and Wantai assay, respectively.</p> <p>Conclusions</p> <p>The HEV seroprevalence in Korean population is about 20% overall, with seroprevalence increasing in this population with increasing age. There was poor concordance in the results of the Genelabs and Wantai assays, which warrants further study concerning a reliable diagnostic test for the diagnosis of hepatitis E.</p>